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CLINICAL TRIALS AND OBSERVATIONS
Splenic marginal zone lymphoma: a prognostic model for clinical use
Luca Arcaini, Mario Lazzarino, Nora Colombo, Sara Burcheri, Emanuela Boveri, Marco Paulli, Enrica Morra, Marcello Gambacorta,
Sergio Cortelazzo, Alessandra Tucci, Marco Ungari, Achille Ambrosetti, Fabio Menestrina, Lorella Orsucci, Domenico Novero,
Alessandro Pulsoni, Maurizio Frezzato, Gianluca Gaidano, Daniele Vallisa, Viviana Minardi, Claudio Tripodo, Vincenzo Callea, Luca Baldini,
Francesco Merli, Massimo Federico, Vito Franco, and Emilio Iannitto, for the Intergruppo Italiano Linfomi
The Integruppo Italiano Linfomi (IIL) car-
ried out a study to assess the outcomes
of splenic marginal zone lymphoma and
to identify prognostic factors in 309 pa-
tients. The 5-year cause-specific survival
(CSS) rate was 76%. In univariate analy-
sis, the parameters predictive of shorter
CSS were hemoglobin levels below 12
g/dL (P < .001), albumin levels below 3.5
g/dL (P  .001), International Prognostic
Index (IPI) scores of 2 to 3 (P < .001),
lactate dehydrogenase (LDH) levels above
normal (P < .001), age older than 60 years
(P  .01), platelet counts below 100 000/
L (P  .04), HbsAg-positivity (P  .01),
and no splenectomy at diagnosis
(P  .006). Values that maintained a nega-
tive influence on CSS in multivariate anal-
ysis were hemoglobin level less than 12
g/dL, LDH level greater than normal, and
albumin level less than 3.5 g/dL. Using
these 3 variables, we grouped patients
into 3 prognostic categories: low-risk
group (41%) with no adverse factors, inter-
mediate-risk group (34%) with one ad-
verse factor, and high-risk group (25%)
with 2 or 3 adverse factors. The 5-year
CSS rate was 88% for the low-risk group,
73% for the intermediate-risk group, and
50% for the high-risk group. The cause-
specific mortality rate ( 1000 person-
years) was 20 for the low-risk group, 47
for the intermediate-risk group, and 174
for the high-risk group. This latter group
accounted for 54% of all lymphoma-
related deaths. In conclusion, with the
use of readily available factors, this prog-
nostic index may be an effective tool for
evaluating the need for treatment and the
intensity of therapy in an individual pa-
tient. (Blood. 2006;107:4643-4649)
© 2006 by The American Society of Hematology
Introduction
Splenic marginal zone B-cell lymphoma is one of the marginal
zone lymphomas (MZLs) recognized by the World Health Organi-
zation (WHO) classification.1,2 The presence of circulating villous
lymphocytes defines splenic lymphoma with villous lymphocytes,3
which is considered the leukemic counterpart of splenic MZL.4 The
relationship between splenic MZL and the other lymphomas of
marginal zone origin and its modality of diffusion are still under
debate.5-7 Diagnosis is traditionally based on spleen histology,
presence of circulating villous lymphocytes, or both. Evaluation of
the bone marrow infiltration pattern has been proposed as a reliable
diagnostic criterion to replace histologic examination of the
spleen.8 Most patients are asymptomatic at diagnosis and may not
require treatment for years. The disease commonly pursues an
indolent course9,10; median overall survival time exceeds 10
years.11 However, the disease follows an aggressive course in
approximately one third of patients, who die within 4 years after
diagnosis.12 Patients with an aggressive clinical course are more
likely to have the 7q31 deletion, to lack IgVH somatic mutations, or
both.13 Clinical and biologic prognostic factors reported thus far for
splenic MZL are heterogeneous.14 The International Prognostic
Index (IPI) score, initially proposed for aggressive lymphoma15 and
validated for low-grade lymphoma,16 has no value in splenic
MZL.17 It has been reported that survival time is significantly
shorter in patients with a monoclonal component, high 2-
microglobulin level, leukocyte count greater than 20 000/L, and
lymphocyte count greater than 9000/L.17 In a series of patients
with splenic MZL with villous lymphocytes, those who underwent
splenectomy fared better than those who received chemotherapy.11
In fact, splenectomy is considered the treatment of choice for
splenic MZL, especially if cytopenias are present.11,17
There is still no reliable clinical score system to provide an
effective prognostic stratification of patients with splenic MZL.
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The Intergruppo Italiano Linfomi (IIL) carried out a multicenter
study of clinical features and outcomes of patients with this
uncommon lymphoma, the aim of which was to build a prognostic
model for splenic MZL. Here we report the results of this study
performed on 309 patients, and we describe a simple prognostic
model for clinical use.
Patients and methods
We studied 309 patients with splenic B-cell marginal zone lymphoma, with
or without villous lymphocytes, diagnosed between March 1989 and March
2004. Approval for this retrospective study, which was based on the use of
archival data, was obtained from the Institutional Review Board of the
Intergruppo Italiano Linfomi (IIL, Modena, Italy). Data management and
analysis were performed in accordance with the ethical guidelines of the
Modena Cancer Registry and the tenets of the Declaration of Helsinki of
1964, as revised in 2000. Spleen and bone marrow specimens were
histologically reviewed by the panel of hematopathologists participating in
the study and were classified according to WHO criteria.1,2 Histologic
findings were combined with clinical, immunophenotypic, and laboratory
data, including the following hallmarks: (1) detection of clonal, light
chain–restricted, circulating CD19/CD20 B lymphocytes negative for
CD5, CD10, CD23, and CD25; (2) greater than 10% typical villous
lymphocytes in the peripheral blood; and (3) intrasinusoidal bone marrow
infiltration by CD20CD5CD10 mature B lymphocytes. Patients with-
out clinically palpable splenomegaly were included if they had typical bone
marrow infiltration by CD20CD5CD10 mature B lymphocytes and
peripheral blood involvement.5 A preliminary database of 372 patients was
established, from which 63 patients were excluded for one or more of the
following reasons: poor histomorphology, incomplete clinical data, diagno-
sis on the basis of cytology and flow cytometry only. Ninety-one patients
from 2 previously published studies are included in the present series.9,10
Mucosa-associated lymphoid tissue (MALT) localization of lymphoma was
not observed in any patient at diagnosis. Demographic characteristics,
clinical symptoms, hematologic features, treatment, type of response,
response duration, and cause of death were the data analyzed. Clinical and
hematologic data were obtained before splenectomy.
Treatment
Eighty-one patients were observed without treatment. One hundred twenty-
four underwent splenectomy (followed by no treatment, 75; chemotherapy,
47; interferon treatment, 2), 88 received chemotherapy only (alkylating
agent, 40; anthracycline-containing regimen, 26; fludarabine-based regi-
men, 9; pentostatin, 8; cyclophosphamide, vincristine, prednisone [CVP],
5), 5 received immunochemotherapy, 3 received therapy with rituximab as a
single agent, 4 received splenic radiotherapy, and 4 received interferon
treatment alone.
Response criteria
Complete remission (CR) was defined as the complete disappearance of all
detectable sites and symptoms of disease. Partial response (PR) was defined
as a greater than 50% reduction in disease localizations. Progressive disease
(PD) was defined as a greater than 25% increase in size of previously
documented disease or the appearance of disease at any site. Shift to a more
aggressive histologic pattern was also considered PD.
Statistical methods
Numeric variables are summarized by their medians and ranges. Categori-
cal variables are described by counts and relative frequencies. Association
between splenic MZL and the categorical variables was tested with the
Fisher exact test (for 2  2 tables) or with 2 approximation for larger
tables. The Kaplan-Meier product-limit method was used to estimate
survival curves, and the log-rank test was adopted to carry out comparisons
between different groups of patients. For each patient, overall survival (OS)
was calculated as the time between the date of diagnosis and the date of
death or last follow-up for censored cases. Cause-specific survival (CSS)
was calculated as the time between the date of diagnosis and the date of
lymphoma-related death or last follow-up for censored cases. Event-free
survival (EFS) was calculated as the time from the date of first-line therapy
until the date of event (treatment after an initial watch-and-wait policy,
relapse or progression of disease, death from any cause). Variables analyzed
for influence on OS and CSS in the entire series were sex; age older than 60
years; lactate dehydrogenase (LDH) greater than normal value; largest
spleen diameter greater than 20 cm; presence of bone marrow involvement;
bone marrow involvement greater than 20% and greater than 30%,
respectively; nodal disease; thoracic lymph nodes; superficial lymph nodes;
hepatic involvement; extranodal sites (1 vs more than 1); performance
status (ECOG 0-1 vs ECOG 2-3); Ann Arbor stage (I-II vs III-IV); IPI score
(0-1 vs 2-3); hemoglobin level less than 12 g/dL; platelet count less than
100 000/L; blood involvement; leukocyte count less than 3500/L,
greater than 20 000/L, greater than 30 000/L; villous lymphocytes (yes
vs no); lymphocyte count less than 4000/L, greater than 9000/L, greater
than 16 000/L; 2-microglobulin level greater than 3 mg/mL; albumin
level less than 3.5 g/dL; serum monoclonal component; HCV-serology
(positive vs negative); HbsAg (positive vs negative); presence of B
symptoms; splenectomy (yes vs no); chemotherapy (yes vs no); anthracy-
cline-containing regimen (yes vs no); CR vs non-CR; autoimmune back-
ground; and history of other neoplasm. Factors independently associated
with OS and CSS were identified in multivariate analysis by the Cox
proportional hazard regression model. The multivariate model included all
variables observed at diagnosis that significantly affected survival in
univariate analysis. The limit of significance for all analyses was defined as
P at or below .05.Variables associated with the highest hazard ratios (HRs)
and lowest P values in multivariate Cox regression were then included in
the computation of the prognostic model. Because HRs were of comparable
magnitude, all factors were given the same weight; the presence of a risk
factor contributed to the score with an increment of 1. Patients with 2 or 3
risk factors were grouped because of the small number of patients in the
highest risk group. The prognostic value of the score was assessed by
comparing survival in the different prognostic categories of the whole
data set and within clinical groupings. All computations were performed
using Statistica 7.1 (StatSoft, Tulsa, OK) and Excel 97 (Microsoft,
Redmond, WA).
Results
Clinical features
Clinical presenting features are summarized in Table 1. Of 309
patients (151 men, 158 women; median age, 64 years; range, 33-86
years), 296 received their diagnosis while in stage IV disease.
Splenomegaly was detected at diagnosis in 290 patients (94%); 177
patients (59%) had peripheral blood involvement, and 38 patients
(13%) had greater than 10% circulating villous lymphocytes in
peripheral blood. Bone marrow was involved in 289 patients
(94%). B symptoms were present in 61 patients (20%). Thirty
patients (10%) had a poor performance status (ECOG score 2 or
higher), 145 (48%) had hemoglobin levels below 12 g/dL, and 71
patients (24%) had platelet counts below 100 000/L. Leukocyte
counts were less than 3500/L in 55 patients (18%), and lympho-
cyte counts were greater than 9000/L in 77 patients (26%). LDH
levels were above normal in 76 patients (28%). Twenty-five
patients (8%) had a monoclonal component (19 IgM, 4 IgG, 1
IgG/IgM, and 1 IgA), with a median concentration of 1 g/dL.
Autoimmune manifestations were detected in 28 patients (9%), as
follows: autoimmune hemolytic anemia, 10 patients; immune
thrombocytopenia, 2; vasculitis, 2; laboratory abnormalities with-
out clinical signs of autoimmune disease, 14. IPI score was
applicable to 270 patients; 60 (22%) ranked in the low-risk, 144
4644 ARCAINI et al BLOOD, 15 JUNE 2006  VOLUME 107, NUMBER 12 only.
For personal use at MODENA MED CLINIC on February 28, 2012. bloodjournal.hematologylibrary.orgFrom 
(54%) in the low-intermediate–risk, 60 (22%) in the intermediate-
high–risk, and 6 (2%) in the high-risk groups. Twenty-four second
cancers were registered (antecedent in 10, concomitant in 4,
subsequent in 10). The overall response rate was 88% (30% CR,
58% PR). In particular, 25% of patients treated with chemotherapy
entered CR and 51% entered PR. Among patients who underwent
splenectomy alone, 20% entered CR and 80% entered PR. Among
those who underwent splenectomy followed by chemotherapy,
60% entered CR and 37% entered PR.
Serologic testing for HCV was performed in 255 patients (83%), and
results were positive in 49 patients (19%). Of 56 patients tested for
HCV-RNA, 25 (45%) had positive findings. No patient had negative
serologic and positive HCV-RNA. Genotype was available for 15
patients (1b in 10, 2b in 1, and 2a/2c in 4) Cryoglobulins were detected
in 13 of 130 patients tested. HbsAg was positive in 13 (5%) of 246
patients tested. We compared the clinical features of HCV-positive and
HCV-negative patients (Table 2). The 2 cohorts differed significantly
regarding the male-female ratio, B symptoms, nodal disease, abdominal
nonlocoregional lymph nodes, presence of villous lymphocytes, cryo-
globulins, and monoclonal component. CR was achieved in 62% of
HCV-negative patients and in 46% of HCV-positive patients (P .04).
Outcome
Mean follow-up time was 3.1 years (with 40% and 20% of patients
followed up for longer than 3 and 5 years, respectively); 56 patients
died (46 of disease-related causes, 4 of cardiovascular disease, 1 of
solid cancer, and 5 of unknown causes). Five- and 10-year OS for
the entire series were 72% (95% confidence interval [95% CI],
65%-79%) and 65% (95% CI, 56%-74%), respectively. Five- and
10-year cause-specific survival (CSS) were 76% (95% CI, 69%-
82%) and 70% (95% CI, 61%-79%), respectively (Figure 1). The
median survival time of patients who died was 1.6 years (range,
0.7-13.5 years). Of patients followed up with no treatment, 82%
were expected to be alive at 5 years. Of those who received
up-front therapy, 67% were expected to be alive at 5 years. Five-
and 10-year EFS for all patients were 41% (95% CI, 33%-48%) and
19% (95% CI, 7%-31%), respectively. Five- and 10-year histologic
shift rates were 5% (95% CI, 2%-10%) and 7% (95% CI, 2%-12%),
respectively. Seven patients (2%) had disease relapse or disease
progression to a MALT site during follow-up.
Univariate analysis
In univariate analysis, the following parameters were predictive of
shorter OS and CSS (Table 3): hemoglobin level less than 12 g/dL,
serum albumin level less than 3.5 g/dL, IPI score 2 to 3, LDH level
higher than normal, age older than 60 years, platelet count less than
100 000/L, HbsAg-positivity, and no splenectomy at diagnosis.
The following parameters were predictive of shorter EFS: use of
chemotherapy (P  .001), no splenectomy at diagnosis (P  .001),
platelet count below 100 000/L (P  .01), hemoglobin level
below 12 g/dL (P  .001), IPI score of 2 to 3 (P  .004), LDH
level above normal (P  .008), serum albumin level below 3.5
g/dL (P  .01), use of an anthracycline-containing regimen
(P  .01), absence of CR (P  .01), nodal disease (P  .02), and
B symptoms (P  .05).
Prognostic model
In multivariate analysis, the 3 parameters that maintained a
negative prognostic influence on OS and CSS were hemoglobin
level less than 12 g/dL, LDH level higher than normal, and albumin
level less than 3.5 g/dL (Table 4). The 3 parameters maintained
statistical significance in multivariate analysis after adjusting for
HCV status, and the hazard ratio associated with HCV infection
was not statistically different from 1. The same applies to the use of
anthracyclines.
With the use of these 3 variables, we constructed a prognostic
model in 232 patients. This model identified 3 prognostic groups
with different OS and CSS (Figure 2; P  .001 for OS and CSS):
group 1, low-risk (41%), with no adverse factors; group 2,
intermediate-risk (34%), with one adverse factor; group 3, high-
risk (25%), with 2 or more adverse factors. The 5-year CSS was
88% (95% CI, 77%-98%) for the low-risk group, 73% (95% CI,
58%-88%) for the intermediate-risk group, and 50% (95% CI,
33%-67%) for the high risk group. The cause-specific mortality
rate ( 1000 person-years) was 20 for the low-risk group, 47 for
the intermediate-risk group, and 174 for the high-risk group (Table
5). The high-risk group accounted for 54% (n  25) of all
lymphoma-related deaths, whereas the low- and intermediate-risk
groups accounted for 16% (n  7) and 30% (n  14) of all
lymphoma-related deaths, respectively. In addition, EFS curves for
the 3 prognostic categories were significantly different (P  .01).
OS and CSS of the 232 patients for whom all 3 parameters included
in the prognostic model were available, and those of the remaining
77 patients in this study did not differ statistically (P  .1).
The distribution of patients treated up front (either by splenec-
tomy or chemotherapy) among the 3 prognostic categories was
Table 1. Clinical features of 309 patients with splenic MZL
No. patients
(%)
No. not available
for assessment
Men/women 151/158 (49/51) 0
Ann Arbor stage 0
I-II 9 (3)
III-IV 300 (97)
Splenomegaly 290 (94) 0
Bone marrow involvement 289 (94) 0
More than 1 extranodal site 45 (15) 0
Nodal disease 128 (41) 0
ECOG status 2 or greater 30 (10) 19
B symptoms 61 (20) 0
Liver involvement 52 (17) 0
Leukemic disease 177 (59) 7
Leukocyte count less than 3500/L 55 (18) 5
Lymphocyte count above 9000/L 77 (26) 16
Presence of villous lymphocytes 55 (18) 0
Hemoglobin level less than 12 g/dL 145 (48) 6
Platelet count less than 100 000/L 71 (24) 7
LDH level higher than normal 76 (28) 36
2-microglobulin level higher than normal 121 (69) 134
Albumin level less than 3.5 g/dL 34 (14) 66
Serum monoclonal component 25 (8) 0
IgG 4 0
IgM 19 0
IgG/IgM 1 0
IgA 1 0
	/
 20/5 0
Autoimmune background 28 (9) 0
Second cancer 24 (8) 0
IPI score 39
Low 60 (22) 0
Low-intermediate 144 (54) 0
High-intermediate 60 (22) 0
High 6 (2) 0
Median age was 64 years (range, 33-86 years).
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statistically different (P  .001) from the distribution of patients in
whom treatment was deferred.
Among patients treated up front, 32% were in the low-risk
group, 38% in the intermediate-risk group, and 30% in the
high-risk group. Among patients who received no therapy, the
percentages were 65%, 23%, and 12%, respectively. The percent-
age of patients who received up-front treatment increased from
56% in the low-risk group, to 81% in the intermediate-risk group,
to 85% in the high-risk group. We also compared the use of
chemotherapy across the 3 prognostic categories: 56% of patients
in the low- and intermediate-risk groups received chemotherapy
compared with 73% in the high-risk group (P  .05). The use of
splenectomy was more frequent in the low- and intermediate-risk
categories (57%) than in the high-risk group (33%) (P  .006).
Split sample analysis
Even though the number of patients appeared relatively small to
build a priori the prognostic model with a 2-step procedure (testing
sample and validation sample), to demonstrate the robustness of
our model we made the prognostic analysis after splitting the study
population in 2 parts (two thirds and one third). Based on univariate
analysis in two thirds of patients (n  206) randomly chosen, the
following parameters were predictive of shorter CSS: LDH level
greater than normal (P  .001), hemoglobin level less than 12 g/dL
(P  .002), serum albumin level less than 3.5 g/dL (P  .007), B
symptoms (P  .03), platelet count less than 100 000/L (P  .02),
and nodal disease (P  .01). In multivariate analysis, the highest
hazard ratios were reached by anemia (HR  2.8), high LDH level
(HR  3.1), and hypoalbuminemia (HR  2). However, because
of the reduced number of patients, only anemia and high LDH level
had significant P values (P  .03 and P  .01, respectively),
whereas hypoalbuminemia did not (P  .1). The prognostic model,
obtained by selecting the 3 variables with the highest HRs, still
identified 3 prognostic groups (0 factors, 1 factor, 2 or more
factors) with statistically different CSS (P  .001). This was
Figure 1. OS and CSS of 309 patients with splenic MZL.
Table 2. Comparison of HCV-positive and HCV-negative patients with splenic MZL
Not available for
assessment
HCV patients,
no. (%)
HCV patients,
no. (%) P
Total 0 206 49
Men/women 0 110/96 16/33 .01
Age older than 60 y 0 132 (64) 28 (57) NS
Ann Arbor stage 0 NS
I-II 6 (3) 0
III-IV 200 (97) 49 (100)
Splenomegaly 0 193 (94) 48 (98) NS
Bone marrow involvement 0 196 (95) 45 (92) NS
More than 1 extranodal site 0 32 (16) 6 (12) NS
Nodal disease 0 84 (41) 28 (57) .05
Locoregional lymph nodes 0 16 (8) 4 (8) NS
Abdominal nonlocoregional lymph nodes 0 46 (22) 21 (43) .006
Liver involvement 0 34 (17) 9 (18) NS
ECOG status 2 or greater 15 18 (9) 4 (8) NS
B symptoms 0 43 (21) 2 (4) .003
Leukemic disease 6 126 (62) 24 (52) NS
Leukocyte count less than 3500/L 3 32 (16) 10 (21) NS
Presence of villous lymphocytes 0 44 (21) 3 (6) .01
Hemoglobin level less than 12 g/dL 4 92 (45) 25 (53) NS
Platelet count less than 100 000/L 5 50 (25) 12 (25) NS
LDH level higher than normal 24 50 (26) 12 (30) NS
2-microglobulin level higher than normal 106 83 (67) 20 (80) NS
Serum monoclonal component 32 35 (19) 18 (40) .005
Albumin level less than 3.5 g/dL 48 26 (16) 5 (12) NS
Cryoglobulins 135 1 (1) 10 (40) .001
HBsAg-positivity 20 8 (4) 3 (7) NS
NA indicates not available; NS, not significant.
Table 3. Clinical parameters influencing OS and CSS in
univariate analysis
OS, P CSS, P
Hemoglobin level less than 12 g/dL .001 .001
Albumin level less than 3.5 g/dL .001 .001
IPI score 2-3 .001 .001
LDH level higher than normal .001 .001
Age older than 60 y .004 .01
HbsAg positivity .01 .01
Platelet count below 100 000/L .02 .04
No splenectomy .05 .006
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applicable to the 154 patients in the testing sample for whom all 3
parameters were available (Figure 3). When applied to the remain-
ing one third of patients (total, 103 patients; 78 had all 3 available
parameters), the prognostic model maintained statistical signifi-
cance (P  .004; Figure 4).
Discussion
Splenic MZL is a well-defined neoplasm that commonly follows an
indolent course. The outcome of the disease, however, is heteroge-
neous. Most patients display a stable clinical course and do not
require treatment for years, but in approximately one third of
patients the disease follows an aggressive course and eventually
causes death within 4 years.12 We studied clinical features and
outcomes of a large series of patients with splenic MZL. The aim
was to build a prognostic model to stratify patients at diagnosis into
different risk categories.
This study provides a prognostic score for splenic MZL that
combines 3 simple laboratory parameters—hemoglobin, LDH, and
albumin levels. With the use of this model, 3 prognostic categories
were identified with significantly different OS and CSS (Figure 2).
The low-risk group was composed of 41% of the patients, all of
whom were asymptomatic and whose lymphoma followed a true
indolent course; disease-specific survival rate at 5 years was 88%.
Conversely, the high-risk group was composed of 25% of the
patients, 54% of whom eventually died of lymphoma. Identifying a
subgroup with a worse prognosis seems particularly important for
an indolent disorder such as splenic MZL, in which the indication
for treatment is often uncertain. This model confirms the impor-
tance of anemia in the prognosis of lymphoproliferative disorders.
The same degree of anemia (less than 12 g/dL) is one of the adverse
factors included in the IPI score for aggressive lymphoma15 and in
the Follicular Lymphoma IPI (FLIPI) score for follicular lym-
phoma.18 Anemia proved to negatively influence OS in a smaller
series of patients with splenic MZL.10 Low serum albumin
concentration, another adverse factor in this prognostic model,
proved to be of prognostic value in other scores for malignant
lymphomas, such as Hodgkin lymphoma.19
Recently, new prognostic markers have been proposed for
splenic MZL on the basis of tissue and cDNA microarray studies.20
Shorter survival was associated with CD38 expression, naive IgVH
genes, and NF-	B pathway gene expression (TRAF5, REL, PKCA).
The use of these complex techniques confirms the existence of a
subset of MZL patients with more aggressive disease.
A possible limitation of our analysis is represented by the
relatively short follow-up, although 40% and 20% of patients were
followed up for longer than 3 and 5 years, respectively. We
excluded patients with dated diagnoses and with inadequate or
incomplete data. A qualifying aspect of this study was the accuracy
of diagnosis; in fact, we included only patients for whom good
quality clinical, histologic, and immunophenotypic data were
available at diagnosis. The long median survival time of patients
with splenic MZL is well known.11 Our analysis focused on
detecting the subset of patients who, though affected by a condition
whose course is commonly considered indolent, have unfavorable
outcomes. Identifying this subset might allow the application of
more intensive treatment programs.
A 2-step procedure is usually required for building a prognostic
index (1 for building and 1 for validation). In the field of
lymphoma, this procedure has been used to build and to validate
prognostic scores for common subtypes (eg, the FLIPI score for
follicular lymphoma).18 Although the present series is the largest
ever reported (309 patients), the number of study patients remains
Figure 2. CSS of 233 patients with splenic MZL according to the 3 categories of
the prognostic model.
Figure 3. CSS of 154 patients with splenic MZL, according to the 3 categories of
the prognostic model. Calculation on two thirds (n  206) of the study population.
Table 4. Clinical parameters influencing OS and CSS
in multivariate analysis
OS CSS
HR P HR P
Hemoglobin level less than 12 g/dL 2.7 .005 2.5 .02
LDH level higher than normal 2.2 .008 3.0 .001
Albumin level less than 3.5 g/dL 3.2 .001 2.9 .005
Table 5. OS, CSS, deaths, and mortality rates of patients with
splenic MZL grouped in the 3 categories
of the prognostic model
Low risk
Intermediate
risk High risk
5 y OS, % (95% CI) 83 (71-94) 72 (58-85) 56 (37-74)
10 y OS, % (95% CI) 83 (71-94) 72 (58-85) NR
5 y CSS, % (95% CI) 88 (77-98) 73 (58-88) 50 (33-67)
10 y CSS, % (95% CI) 88 (77-98) 73 (58-88) NR
Deaths, % 20 31 49
Cause-specific deaths, % 16 30 54
Mortality rate, 1000 p-y 27 60 201
Cause-specific mortality rate, 1000 p-y 20 47 174
NR indicates not reached; p-y, person-years.
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relatively small; as a consequence, partitioning the patients into 2
subgroups could have weakened the study’s statistical power.
However, we performed the analysis on a two thirds/one third
partition of the study population, with the aim of demonstrating the
robustness of the model. Multivariate analysis of two thirds of the
patients showed high hazard ratios for the same 3 parameters that
were valid for the entire population; in this subgroup, we were able
to define 3 groups with statistically different CSS. The model was
also effective in the remaining one third of patients.
In splenic MZL, splenectomy plays a dual role: diagnostic and
therapeutic. Regarding diagnosis, surgical removal of the spleen is
not essential because the integration of clinical data with bone
marrow histology and flow cytometry enables a diagnosis without
the need for surgery. Splenectomy, however, is considered the
treatment of choice for patients with peripheral cytopenia or
abdominal symptoms caused by an enlarged spleen.11,17,21 It has
been shown that the extent of bone marrow infiltration by
lymphoma may increase after splenectomy.22 As in previous
reports, this study highlights that splenectomy is related to better
OS and CSS as determined with univariate analysis. In multivariate
analysis, however, splenectomy did not retain an independent
prognostic value. Patients in low- and intermediate-risk prognostic
categories more frequently underwent splenectomy. It is arguable
that a significant proportion of these splenectomies were performed
mainly for diagnostic purposes.
In this study, the HCV seroprevalence in patients with splenic
MZL was 19%; this percentage was considerable despite the high
seroprevalence of HCV infection in the Italian population.23
However, the association of HCV infection with splenic MZL has
not been found in other series.17 A new clinical entity characterized
by concurrent splenic MZL with villous lymphocytes, type II
cryoglobulinemia, and HCV infection has been proposed.24 The
reported antilymphoma activity of interferon- in patients with
HCV-positive splenic MZL24,25 and with other types of MZL26,27
supports a role for HCV infection in the lymphomagenesis of
marginal zone lymphomas.
In conclusion, this study of a large population of patients shows
that splenic MZL has a heterogeneous clinical behavior. Using
readily available clinical factors, we designed a simple prognostic
model that identified 3 categories with significantly different
survival. Ongoing research on features closely related to the
biology of the disease, such as karyotypic abnormalities, IgVH gene
mutational status, and gene expression profile, might shed light on
the biologic heterogeneity of this type of lymphoma. For clinical
use, this prognostic model, based on simple variables, may be a
useful tool to stratify patients in different risk groups, to establish
the need for therapy, and to compare different treatment modalities.
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Appendix
Participating institutions and principal investigators of the Intergruppo
Italiano Linfomi on splenic marginal zone lymphoma are as follows:
Division of Hematology, IRCCS Policlinico San Matteo, University of
Pavia, Pavia (Luca Arcaini, Nora Colombo, Sara Burcheri, Francesco
Passamonti, Cristiana Pascutto, Mario Lazzarino); Division of Pathology,
IRCCS Policlinico San Matteo, University of Pavia, Pavia (Marco Paulli,
Emanuela Boveri, Marco Lucioni, Umberto Magrini); Division of Hematol-
ogy, University of Palermo (Viviana Minardi, Emilio Iannitto); Division of
Pathology, University of Palermo (Claudio Tripodo, Vito Franco); Division
of Hematology, Ospedale Niguarda Ca’ Granda, Milano (Livio Gargantini,
Giovanna D’Avanzo, Enrica Morra); Division of Pathology, Ospedale
Niguarda Ca’ Granda, Milano (Marcello Gambacorta); Division of Hema-
tology, Ospedali Riuniti Bergamo (Andrea Rossi, Sergio Cortelazzo);
Division of Hematology, Ospedali Civili, Brescia (Alessandra Tucci,
Giuseppe Rossi); Division of Pathology, Ospedali Civili, Brescia (Marco
Ungari); Department of Clinical and Experimental Medicine, University of
Verona, Verona (Achille Ambrosetti, Maura Colosio, Giovanni Pizzolo);
Department of Pathology, University of Verona, Verona (Fabio Menest-
rina); Division of Hematology, Azienda Ospedaliera S. Giovanni Battista,
Torino (Lorella Orsucci, Umberto Vitolo, Eugenio Gallo); Division of
Pathology, Azienda Ospedaliera S. Giovanni Battista, Torino (Domenico
Novero); Department of Hematology, University “La Sapienza” University,
Roma (Alessandro Pulsoni, Natalia Frattarelli, Robin Foa); Division of
Hematology, Ospedale S. Bortolo, Vicenza (Maurizio Frezzato, Francesco
Rodeghiero); Division of Pathology, Ospedale S. Bortolo, Vicenza (Eman-
uela Bonoldi); Division of Hematology, Amedeo Avogadro University of
Eastern Piedmont, Novara (Davide Rossi, Gianluca Gaidano); Division of
Pathology, Ospedale Maggiore, Novara (Antonio Ramponi); Bone Marrow
Transplant Unit, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio
Calabria (Caterina Stelitano, Vincenzo Callea); Department of Hematology,
IRCCS Ospedale Maggiore, University of Milano, Milano (Luca Baldini,
Maria Goldaniga, Giorgio Lambertenghi Deliliers); Division of Medicine
and Hematology, Ospedale G. da Saliceto, Piacenza (Daniele Vallisa,
Patrizia Bernuzzi, Luigi Cavanna); Division of Hematology, Ospedale S.
Maria Nuova, Reggio Emilia (Francesco Merli, Luigi Gugliotta); Department of
Oncology and Hematology, University of Modena and Reggio Emilia, Modena
(Stefano Luminari, Monica Bellei, Massimo Federico); Division of Hematology,
University of Parma (Monica Crugnola, Vittorio Rizzoli); Division of Hematol-
ogy, Ospedale S. Paolo, Milano (Lilj Uziel); Division of Pathology, Ospedale S.
Paolo, Milano (Umberto Gianelli); Division of Medical Oncology A, National
Cancer Institute, Aviano (Michele Spina, Umberto Tirelli); Division of Hematol-
ogy, Ospedale S. Croce, Cuneo (Roberta Calvi, Silvia Tavera,Andrea Gallamini);
Division of Hematology, Policlinico S. Maria alle Scotte, University of Siena
(Alberto Fabbri, Francesco Lauria); Division of Hematology, Polytechnic
University of Ancona, Ancona (Mauro Montanari, Pietro Leoni); Department of
Hematology, Catholic University Medical School, Roma (Annalaura Di Febo,
Maria Teresa Voso); Department of Hematology, Ospedale S. Maurizio, Bolzano
(Atto Billio, Paolo Coser); Division of Hematology, University “Federico II,”
Napoli (Amalia De Renzo, Bruno Rotoli); Division of Hematology, Azienda
Ospedaliera Pugliese-Ciaccio, Catanzaro (Renato Cantaffa); Division of Hema-
tology, University of Padova (Giampietro Semenzato); Division of Hematology,
Ca` Foncello Hospital (Filippo Gherlinzoni); and Division of Hematology,
Ospedale di Circolo, Rho (Alessandro Vismara), Italy.
Figure 4. CSS of 78 patients with splenic MZL according to the 3 categories of
the prognostic model. Calculation on one third (n  103) of the study population.
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